Dr. Cowan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
617 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-7348Fax+1 206-606-1043- Is this information wrong?
Summary
- As an associate professor of medicine in the Div. of Medical Oncology at the University of Washington School of Medicine, my focus is in plasma cell disorders, specifically, MM and AL amyloidosis. I am involved in a variety of clinical research projects, both retrospective and prospective studies. I have a special interest in multiple myeloma and AL amyloidosis.
My clinical and research focus is on immunotherapy for MM, including CAR T cells; health services research in MM, and health informatics.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2012 - 2015
Boston University Medical CenterResidency, Internal Medicine, 2009 - 2011- Boston University Medical CenterInternship, Internal Medicine, 2008 - 2009
- University of Washington School of MedicineClass of 2008
Certifications & Licensure
WA State Medical License 2017 - 2025
AK State Medical License 2022 - 2024
MA State Medical License 2011 - 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Start of enrollment: 2016 Aug 29
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Start of enrollment: 2017 Nov 07
- A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.Adeel M Khan, Georgia McCaughan, Xiaoliang Wang, James Roose, Larry D Anderson Jr, Fieke W Hoff, Rahul Banerjee, Bo Wang, Andrew J Cowan, S Vincent Rajkumar, Gurbakhas...> ;Blood Cancer Journal. 2024 Mar 22
- Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma.Marivel Ortega, Constance Missimer, Masumi Ueda Oshima, Rahul Banerjee, Andrew J Cowan, Paul A Carpenter, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 23
- Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
- Join now to see all
Abstracts/Posters
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma SecretaseAndrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Clinical Challenges: Quadruplet Therapy in Multiple MyelomaJune 1st, 2021
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019
Grant Support
- T32 Oncology Training GrantNIH2014–2015
Committees
- Reviewer, Scientific Review Committee, FHCRC 2016 - Present
Professional Memberships
- Member
- Fellow
Hospital Affiliations
UW Medicine/Harborview Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
External Links
- HemOnc.orghttp://hemonc.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
